Sulindac

Discontinued Product

Sulindac (Cat. No. 1707) has been withdrawn from sale for commercial reasons.
Description: Cyclooxygenase inhibitor (following metabolism to sulindac sulfide)
Chemical Name: (1Z)-5-Fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid
Purity: ≥99% (HPLC)
Datasheet
Citations (1)
Reviews
Literature (6)

Biological Activity for Sulindac

Prodrug. Metabolizes to sulindac sulfide, a cyclooxgenase inhibitor that represses ras signaling, and sulindac sulfone, an antitumor agent, following oral administration in vivo. Widely used anti-inflammatory agent.

Technical Data for Sulindac

M. Wt 356.41
Formula C20H17FO3S
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 38194-50-2
PubChem ID 1548887
InChI Key MLKXDPUZXIRXEP-MFOYZWKCSA-N
Smiles FC1=CC=C(/C(C(C)=C3CC(O)=O)=C\C2=CC=C(S(C)=O)C=C2)C3=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for Sulindac

References are publications that support the biological activity of the product.

Haanen (2001) Sulindac and its derivatives: a novel class of anticancer agents. Curr.Opin.Investig.Drugs 2 677 PMID: 11569947

Shen and Winter (1977) Chemical and biological studies on indomethacin, sul. and their analogs. Adv.Drug Res. 12 90 PMID: 343530

Taylor et al (2000) Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res. 60 6607 PMID: 11118042

View Related Products by Target

View Related Products by Product Action

View all Cyclooxygenase Inhibitors

Keywords: Sulindac, Sulindac supplier, Cyclooxygenase, inhibitors, inhibits, COX, Oxygenases, Oxidases, 1707, Tocris Bioscience

1 Citation for Sulindac

Citations are publications that use Tocris products. Selected citations for Sulindac include:

Hagen et al (2015) Comparative Multi-Donor Study of IFNγ Secretion and Expression by Human PBMCs Using ELISPOT Side-by-Side with ELISA and Flow Cytometry Assays. Cells 4 84 PMID: 25679284


Reviews for Sulindac

There are currently no reviews for this product. Be the first to review Sulindac and earn rewards!

Have you used Sulindac?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer Research Product Guide

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Immunology Product Listing

Immunology Product Listing

A collection of over 190 products for immunology research, the guide includes research tools for the study of:

  • Chemokine and Cytokine Signaling
  • Chemotaxis
  • Complement System
  • Immune Cell Signaling
  • Inflammation
Pain Research Product Guide

Pain Research Product Guide

A collection of over 280 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Alzheimer's Poster

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.

Epilepsy Poster

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.

Parkinson's Poster

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.